

A nuclear RNA-binding cyclophilin in human T cells

Huaifeng Mi, Oliver Kops, Esther Zimmermann, Anja Jäschke, Maximilian Tropschug*

Institut für Biochemie und Molekularbiologie der Albert-Ludwigs-Universität, Hermann-Herder-Str. 7, D-79104 Freiburg i.Br., Germany

Received 14 October 1996; revised version received 17 October 1996

Abstract Cyclophilins (CyPs) are binding proteins for the immunosuppressive drug cyclosporin A (CsA). CyPs are evolutionarily highly conserved proteins present in both pro- and eukaryotes as well as in different subcellular locations. CyPs possess enzymatic activity, namely peptidyl-prolyl *cis-trans* isomerase (PPIase) activity; CyPs are involved in cellular protein folding and protein interactions. To date, only cyclosporins and proteins are known to interact with CyPs. Here we describe a novel nuclear cyclophilin (hCyp33) from human T cells with an additional RNA-binding domain. This combines for the first time RNA binding and protein folding in one protein.

Key words: RNA binding; RNP motif; Prolyl isomerase; Cyclophilin; Protein folding; Cyclosporin A

1. Introduction

Cyclophilins (CyPs) are highly conserved proteins present in both pro- and eukaryotes and in different subcellular locations [1–3]. Besides their high-affinity binding of cyclosporin A (CsA), CyPs possess peptidyl-prolyl *cis-trans* isomerase (PPIase) activity, which is inhibited by CsA. Due to the PPIase activity CyPs are able to accelerate protein folding *in vitro* (reviewed in [2,3]). There is increasing evidence that CyPs are involved in cellular protein folding after ribosomal synthesis and after passage of proteins across intracellular membranes [4–8]. CyPs are also involved in transient protein interactions, e.g. with steroid receptors [9], gag protein of HIV [10,11], or rhodopsin [12]. Abundant cytosolic CyPs (hCyp18 in human cells [13] and NcCyp20 [14] in the fungus *Neurospora crassa*) mediate the immunosuppressive [15] or antifungal effect [16], respectively, of CsA by inhibiting the protein phosphatase calcineurin.

In higher eukaryotic cells a variety of CyPs are present in different concentrations and cellular compartments. Abundant small forms (18–24 kDa) are present in the cytosol, mitochondria and the endoplasmic reticulum, perhaps being part of the protein folding machinery [4–8]. Larger CyPs (40–360 kDa) containing additional protein-binding domains are present in hormone receptor complexes [9], nuclear pores [17] or on the cell surface [18]. To date, two kinds of molecules are known to interact with CyPs: cyclic peptides (cyclosporins) and proteins.

Here we describe a novel nuclear cyclophilin (hCyp33) from human T cells. hCyp33 contains two functional domains: an RNA-binding domain at the amino-terminus and a PPIase domain at the carboxy-terminus of the protein. This combines

for the first time RNA binding and protein folding in one protein.

2. Material and methods

2.1. Cloning of a full-length cDNA for hCyp33

PCR amplification of DNA-fragments from different human Jurkat T cell line cDNA libraries were performed with two degenerate primers, which correspond to amino acid sequences QGGDF and KHVVFVG (boxed in Fig. 2b) in the highly conserved regions of known cyclophilins [3,13,17–20]. The resulting PCR products were subcloned into pUC18 and sequenced. Nested PCR was performed to extend the sequence using two libraries: a Marathon cDNA library of the human Jurkat T cell line (Clontech) and a cDNA library made of mRNA from human T cells. Both libraries yielded as longest cDNA one with a length of 1.6 kb. The cDNA was sequenced on both strands.

2.2. Detection of hCyp33 mRNA using Northern hybridization

Human Jurkat T cell poly(A)⁺ RNA (2 µg per lane) was resolved on a formaldehyde gel, blotted onto a nylon membrane and hybridized as described [14].

Jurkat T cells were subfractionated according to [21]. A hCyp33-specific rabbit antiserum was obtained by immunization with a glutathione transferase-fusion protein [22] containing amino acids 67–164 of hCyp33 at the carboxy-terminus.

2.3. *In vitro* expression

A full-length cDNA coding for hCyp33 was subcloned into pGEM4. Coupled *in vitro* transcription/translation using ³⁵S-labeled methionine was performed in a TNT SP6 coupled reticulocyte lysate system (Promega) according to the manufacturer's protocol.

Nucleic acid binding assays were performed using ³⁵S-labeled hCyp33 from the *in vitro* expression system (see Fig. 4a, lane 1) as described [23].

PPIase assays were performed in a standard peptide assay [24] using a GST-hCyp33 fusion protein and Suc-Ala-Ala-Pro-Phe-pNA as a substrate.

3. Results

A variety of different cyclophilins have been cloned from higher eukaryotic cells (reviewed [1–3]). Using a CsA affinity column, we recognized minor bands in addition to the known CyPs (unpublished data). We therefore used a PCR approach to identify new CyPs from the human T cell line Jurkat. Degenerate primers directed against regions which are highly conserved in known CyPs (QGGD and KHVVFVG; see boxes in Fig. 2b) were used to amplify short DNA fragments from different Jurkat cDNA libraries. Ninety CyP-related cDNA fragments were cloned and sequenced. Sixty-nine clones were identified as part of the coding region of human Cyp18 [13], 19 were identical to secretory hCyp23 [19], one was identical to mitochondrial hCyp22 [20] and one clone (M1) represented a new hCyp. Using additional PCR approaches extending the cDNA sequence (5'- and 3'-RACE) to identify a full-length cDNA, we finally isolated and sequenced a 1.6 kb cDNA. This cDNA codes for a protein of 33 430 Da, which was named hCyp33.

*Corresponding author: Fax: (49) (761) 2035253.

E-mail: tropschu@sun2.ruf.uni-freiburg.de

The amino acid sequence for hCyp33 has been deposited under MIPS accession number S66681.




Fig. 1. hCyP33 contains an RNA-binding domain at the amino-terminus and a cyclophilin domain at the carboxy-terminus. a: Amino acid sequence of hCyP33 derived from the cDNA. b: Domain organization of hCyP33.

Fig. 1a shows the amino acid sequence of hCyP33 derived from the cDNA sequence. Sequence databank comparisons revealed that hCyP33 is a novel protein. Surprisingly, the protein exhibits *two* regions of high sequence identity to other proteins. The first region showed similarities to cyclophilins, as expected, whereas the second region was similar to RNA-binding proteins containing an RNA recognition motif (RRM, also known as RNA-binding domain or RNP consensus sequence; reviewed in [25–27]).

Separate sequence alignments of both domains are shown in Fig. 2. The putative amino-terminal RNA-binding domain of hCyP33 contains both RNP-1 and RNP-2 submotifs (Fig. 2a) located 33 amino acids apart. The RNP-1 octapeptide, Lys/Arg-Gly-Phe/Tyr-Gly/Ala-Phe-Val-X-Phe/Tyr (K/R-G-F/Y-G/A-F-V-X-F/Y), is the most highly conserved segment of the RNP motif (being RGFAFVEF in hCyP33); RNP-2 is a less well conserved hexapeptide that is rich in aromatic

a

		<u>RNP-2</u>			<u>RNP-1</u>	
hCyP33	1	MATTKRVLVYV GGLAEEVDDK	VLHAAFIPFG	DITDIQIPLD	YETEKHRGFA	FVEFELAEDA 60
RBP U2	8	ERNQDATV YV GGLDEKVS EP	LLWELFLQAG	PVVNTHMPLD	RVTGQHQQYG	FVEFLSEEDA 67
12RNP1	1	MSI YV GNLSYEVTEA	DLTAVFTEYG	AVKRVQLPID	RETGRMRGFG	FVEMSADAE 55
RGP-1a	1	MAEVEYRCFV GGLAWATTDQ	TLGEAFSQFG	EILDSKIIND	RETGRSRGFG	FVTFKDEKAM 60
PABP 3	220	NLYV KNINSETTDE	QFQELFAKFG	PIVSASLEKD	ADGKL-KGFG	FVNYEKHEDA 272
hCyP33	61	AAAI DNMNE S	ELFGRTIRVN	LAKP		84
RBP U2	68	DY AIKIMNMI	KLYGKPIRVN	KASA		91
12RNP1	56	D AAIAALGGA	EWMGRGLRVN	KAKP		79
RGP-1a	61	RD AI EGMNGQ	DLDGRNITVN	IAQS		84
PABP 3	273	V KAVEALNDS	ELNGEKLYVG	RAQK		296
b						
hCyP33	137	R SNPQVYMDI	K IGNKPAGRI	Q MLLRSDVVP	M TAE NFRCLC	T HE KGF G... .. F K 185
hCyP18cy	1	MVNPTVFFDI	AVDGEPLGRV	SFELFADKVE	KTAENFRALS	TG EKG F... ..YK 49
hCyP23sec	33	KVTVK VYFDL	RIGDEDVGRV	IFGLFGKTV	KTVDNFVALA	TG EKG F... ..YK 81
hCyP22mito	43	SGNPLVYLDV	DNAGKPLGLV	VLELKADVVP	KTAENFRALC	TG EKG F... ..YK 91
hCyP41cy	13	P SNPRVFFDV	DIGGERVGRV	VLELFADIVP	KTAENFRALC	TG EKG F... HTTGKPLHFK 69
hCyP158mem	58	QDR PQCHF DI	EINREPVGRI	MPQRFS DI CP	KTCKN FLCLC	SGEK G I GH TT KTTGK K LCYK 117
RanBP2	3064	--- PVVFFDV	CADGEPLGRI	TMELFSNIVP	RTAENFRALC	TG EKG F... .. F K 3109
hCyP33	186	G SS F HRIIPQ	F MC Q GG D ET N	H NGTGGK S IY	G KK F DDENFI	L KHTG P GLLS M ANSGP N TNG 245
hCyP18cy	50	G SC F HRIIPG	F MC Q GG D ET R	H NGTGGK S IY	G E K FEDENFI	L KHTG P GILS M ANAGP N TNG 109
hCyP23sec	82	N SK F H R VIKD	F MI Q GG D ET R	G DGTGGK S IY	G ER F PDENFK	L KHY G PGVLS M ANAG K DTNG 141
hCyP22mito	92	G ST F H R VI P S	F MC Q AG D ET R	N HGTGGK S IY	G SP F RDENFT	L KH V GPVLS M ANAGP N TNG 151
hCyP41cy	70	G CF F HRI I KK	F MI Q GG D ES N	Q NGTGGK S IY	G E K FEDENFH	Y KHDLE G LLS M ANAG R NTNG 129
hCyP158mem	118	G ST F H R VVKN	F MI Q GG D ES E	G NGKGG S IY	G GYEK D ENFI	L KHDRA F LLS M ANAG K HTNG 177
RanBP2	3110	N S I F H RVIPD	F VC Q GG D IT K	H DGTGG Q S I Y	G DK F EDENFD	V KHTG P GLLS M AN Q Q N TNN 3169
hCyP33	246	S QFFLTCDKT	D WLDG K H V VF	G EVTEGLDVL		275
hCyP18cy	110	S QFFICTAKT	E WLDG K H V VF	G KVKEGMNIV		139
hCyP23sec	142	S QFFITIVKT	A WLDG K H V VF	G EVLEGMEV		161
hCyP22mito	152	S QFFICTIKT	D WLDG K H V VF	G HVKEGMDV		171
hCyP41cy	130	S QFFITTVPT	P HLDG K H V VF	G QVIEGIGVA		159
hCyP158mem	178	S QFFITTKPA	P HLDG K H V VF	G LVISGFIVI		207
RanBP2	3170	S QFVITLKKA	E HLDF K H V VF	G FVKDGMDTV		3199

Fig. 2. Sequence comparisons of the RNA-binding domain (a) and PPIase (cyclophilin) domain (b) of hCyP33. a: Alignment of amino acids 1–84 of hCyP33 with RNA-binding domains (RNP-2 and RNP-1) of the following proteins: RBP U2, human spliceosome-associated protein SAP 49 [29]; *Synechococcus* 12 RNP1 [23]; RGP-1a, an RNA-binding protein in wood tobacco [30] and PABP 3, a yeast poly(A)-binding protein [31]. The region of two conserved motifs of RNA-binding proteins, RNP-2 and RNP-1 are indicated. b: Alignment of amino acids 137–275 of hCyP33 with the PPIase domains of different cyclophilins: hCyP18cy, human cytosolic cyclophilin A [13]; hCyP23sec, human secreted cyclophilin B [19]; hCyP22mito, human mitochondrial cyclophilin [20]; hCyP41cy, a human cyclophilin present in hormone receptor complexes [32]; hCyP158mem, a plasma membrane cyclophilin of human natural killer cells [18]; RanBP2, a Ran/TC4-binding nucleopore protein [17]. The regions used for initial design of PCR primers to identify hCyP33 are boxed. Identical amino acids are printed in bold type in a and b.




Fig. 3. hCyP33 is a low abundance nuclear protein in human T cells. a: Detection of hCyp33 mRNA using Northern hybridization. Human Jurkat T cell poly(A)⁺ RNA (2 µg per lane) was hybridized to part of the cDNA of hCyp33 (corresponding to amino acid sequence 1–152; lane 1) or the cDNA coding for hCyp18 [13] (lane 2). Exposure times of the autoradiographic films were 2 h for hCyp18 mRNA (lane 2), and 7 days for hCyp33 mRNA (lane 1). b: Immunoblot of different cellular fractions from the human Jurkat T cell line using affinity-purified anti-hCyP33 rabbit antibodies. Jurkat T cells were subfractionated according to [21]; lane 1, 12000×g supernatant of nuclear free cell extract, 2, 12000×g pellet of nuclear free cell extract, 3, 12000×g supernatant of nuclear extract, 4, 12000×g pellet of nuclear extract. The polyclonal rabbit antiserum was obtained by immunisation of a glutathione transferase fusion protein [22] containing amino acids 67–164 of hCyP33 at the carboxyterminus.

and aliphatic amino acids [27] (LYVGGL in hCyP33). In addition, several other amino acids throughout the RNP motif are conserved, when other RNA-binding proteins are compared (see Fig. 2a). The human protein whose RNA-binding domain is most closely related (43.8% identity in a 73 amino acid overlap) to the hCyP33 RNA-binding domain is the spliceosome-associated protein SAP49 (RBP U2 [29]). Other proteins in the identity range of 40% can be found in cyanobacteria (12 RNP1 [23]), an RNA-binding protein from tobacco (RGP-1 [30]) and a yeast poly(A)-binding protein (PABP3 [31]). Despite their different functions, these proteins all share this RNA-binding domain. This domain is typical for a large family of RNA-binding proteins like snRNP proteins, hnRNP proteins and other proteins regulating RNA processing or translation [25–27].

In addition to this putative RNA-binding domain, hCyP33 contains a typical cyclophilin domain (Fig. 2b), which is 70% identical to cytosolic hCyp18 [13], a protein probably involved in protein folding (like *Neurospora crassa* cytosolic and mitochondrial NcCyp20 [7,14,28], E. Zimmermann and M. Tropschug, unpublished data) and stabilization [10,11].

Cytosolic hCyp18 is an abundant protein. We used its cDNA [13] as a control probe in a Northern blot analysis (Fig. 3a, lane 2), which showed its abundant hCyp18 mRNA (0.8 kb); using hCyp33 cDNA as a probe, we recognized a rare mRNA of 1.6 kb (Fig. 3a, lane 1), in the range of

approximately 1/1000 the amount of hCyp18 mRNA. Since the longest hCyp33 cDNA isolated was 1.6 kb long, we conclude that we have cloned a full-length cDNA (see also below).

For antibody production, a GST fusion protein [22] was constructed containing the interconnecting region (amino acids 67–164; see schematic representation in Fig. 1b) between the RNA-binding and the PPIase domain (to avoid cross-reactivity of the antiserum with other CyPs and/or RNA-binding proteins). Polyclonal antibodies were raised in rabbits against the fusion protein and affinity-purified. Jurkat cells were fractionated into nuclei and nuclear-free fractions [21]. These fractions were tested for the presence of hCyp33 in a Western blot analysis. Only nuclear soluble and nuclear insoluble (matrix) fractions showed the presence of a protein with an apparent molecular weight of 33 kDa (Fig. 3b, lanes 3 and 4 respectively). We conclude that hCyp33 is a nuclear protein in Jurkat cells and that we have indeed cloned a full-length cDNA coding for this protein (see above).

Using a coupled transcription/translation system (TNT lysate; Promega), the protein was expressed in vitro from the cDNA cloned into pGEM4. After translation using [³⁵S]methionine as label, total translation products were separated on SDS gels. Fig. 4a (lane 1) shows the result of an in vitro expression experiment. Two major bands with apparent molecular weights of 33 kDa and 30 kDa showed up, the upper band running exactly at the same position in SDS-PAGE as hCyp33 in Western blots (see Fig. 3b, lanes 3, 4). Since both proteins are coded by the same cDNA, we suggest that the 33/30 kDa proteins reflect different forms (e.g. post-translational modifications) of hCyp33. RNA-binding proteins are often phosphorylated in vivo [26,27]. Specific antiserum raised against hCyp33 (see Fig. 1b) precipitated both the 33 kDa and 30 kDa proteins from the reticulocyte lysate with equal efficiency (Fig. 4a, lane 2), showing that both proteins are hCyp33 related. The nature of the differences in both isoforms of hCyp33 are unknown to date.

We used in vitro expressed hCyp33 to test whether the putative RNA-binding domain (Fig. 1b/2a) is functional. Reticulocyte lysate containing [³⁵S]methionine-labeled hCyp33 was incubated with agarose-coupled nucleic acids. Very weak binding was observed using single-stranded (ss) DNA and double-stranded (ds) DNA. Almost no binding was observed using poly(C) or poly(G) columns. In contrast, specific binding was observed on poly(A) and poly(U) columns (see Fig. 4b), suggesting that hCyp33 is indeed an RNA-binding protein with a strong preference for A and U residues. It is interesting to note that only the 33 kDa band produced in reticulocyte lysates was able to bind. This could mean that a posttranslational modification is necessary for efficient binding to RNA. Phosphorylation and dephosphorylation of RNA-binding proteins are known to play an important role in regulation of the activities of these proteins [27].

To test whether the CyP domain (Fig. 2b) of hCyp33 is functional as well and therefore exhibits PPIase activity, a glutathione transferase fusion protein [22] containing hCyp33 at the carboxy-terminus was expressed in *E. coli*, purified using glutathione beads and tested in a peptide-coupled PPIase assay [24].

Indeed, this protein exhibits PPIase activity which can be inhibited by cyclosporin A (CsA; see Fig. 4c). The enzymatic activity of hCyp33 in terms of K_m/K_{cat} values is similar to that




Fig. 4. Both the RNA-binding domain and the CyP domain are functional. a: Expression in vitro and antibody precipitation of hCyP33. A full-length cDNA coding for hCyP33 was subcloned into pGEM4. Coupled in vitro transcription/translation using [³⁵S]methionine as label was performed in a TNT/SP6 coupled reticulocyte lysate system (Promega) (lane 1). In order to confirm that the major bands appearing in lane 1 are related to hCyP33, immunoprecipitation using anti-hCyP33 antiserum was performed (lane 2). b: Nucleic acid binding assays were performed using ³⁵S-labeled hCyP33 from the in vitro expression system (see a, lane 1) as described [23]. Binding was monitored on single-stranded (ss) DNA, double-stranded (ds) DNA, poly(A), poly(C), poly(G) and poly(U), respectively, covalently bound to agarose. c: hCyP33 is active as a CsA-sensitive PPIase. Assays of PPIase activity of hCyP33: ▲ blank, ■ 17 nM GST-hCyP33, □ 17 nM GST-hCyP33 preincubated with CsA. Assays were performed in a standard peptide assay [24] using purified GST-hCyP33 and Suc-Ala-Ala-Pro-Phe-pNA as a substrate. 17 pmol of GST-hCyP33 (± 1.70 nmol CsA) was preincubated at 10°C with 800 μ g/ml chymotrypsin for 5 min in a volume of 995 μ l. The assay was started by the addition of 5 μ l of a 8 mM stock of the substrate. After mixing, the increase in absorbance at 390 nm was monitored.

of hCyP18 (data not shown). In addition to the peptide PPIase assay, we also tested whether hCyP33 is active as a true protein-folding enzyme. Using refolding of urea-denatured mouse dihydrofolate reductase (DHFR) as a model system [7,8], we found that hCyP33 accelerates DHFR refolding; this protein folding activity was in the same range as that for hCyP18 (data not shown) or *Neurospora crassa* NcCyP20 [7]. The enzymatic activities of all three cyclophilins were inhibited by CsA.

In summary, hCyP33 represents a novel nuclear T cell protein, which combines RNA binding and PPIase activities in the same molecule.

4. Discussion

Why might nature combine RNA binding and PPIase activity in one molecule? Known PPIases can play a dual role in protein folding and cellular signalling [15].

hCyP33 could be a regulatory protein which after binding to a specific RNA might bind another protein and perhaps stabilize or alter the folding state of this protein. This protein could in turn affect RNA metabolism. hCyP33 could have a function similar to hCyP40 which is present in nonactive steroid receptor complexes [9]. Transient interactions between PPIases and target proteins are known, as between hCyP18 and the gag protein of HIV. Disruption of this complex by CsA or mutations of critical prolyl residues in gag leads to defective virions [10,11]. Another example of a transient interaction between a cyclophilin and a target protein is the interaction between DmCyP26 (the *ninaA* gene product of *Drosophila melanogaster*), a CyP homolog present in the endoplasmic reticulum, and Rh-1 rhodopsin. DmCyP26 functions like a chaperone, forming a stable complex at least in the maturation process of rhodopsin [12].

hCyP33 could influence RNA processing, modification, transport or translation, either by itself or when bound to another factor. In this context, it is interesting to note that there exists a novel family of PPIases, the parvulin family [34], members of which are essential for regulation of human mitosis (Pin1 [33]) and for RNA maturation in yeast (Ptf1 [35]; H. Domdey and G. Fischer, personal communication). It is tempting to speculate that PPIases play not only a role in protein folding after protein synthesis or after proteins have crossed biological membranes but could also act as on/off switches due to *cis/trans* isomerization of regulatory proteins.

It will be of major interest to investigate which RNA(s) and/or protein(s) bind to hCyP33. A further question is how CsA, which acts as an immunosuppressant by suppressing transcription of specific T cell proteins, might influence these interactions.

Acknowledgements: We thank Nikolaus Pfanner and Marie Follo for critical reading of the manuscript. This work was supported by the Deutsche Forschungsgemeinschaft (Tr284/1-2; SFB 364 and SFB 388) and the Fonds der Chemischen Industrie.

References

- [1] Schreiber, S.L. (1991) *Science* 251, 283–287.
- [2] Schmid, F.X. (1993) *Annu. Rev. Biophys. Biomol. Struct.* 22, 123–143.
- [3] Fischer, G. (1994) *Angew. Chem. Int. Ed. Engl.* 33, 1415–1436.
- [4] Gething, M.-J. and Sambrook, J. (1992) *Nature* 355, 33–45.
- [5] Freedman, R.B., Hirst, T.T. and Tuit, M.F. (1994) *Trends Biochem. Sci.* 19, 331–336.
- [6] Hartl, F.-U. (1996) *Nature* 381, 571–580.
- [7] Rassow, J., Mohrs, K., Koidl, S., Barthelmess, I.B., Pfanner, N. and Tropschug, M. (1995) *Mol. Cell Biol.* 15, 2654–2662.
- [8] Matouschek, A., Rospert, S., Schmid, K., Glick, B.S. and Schatz, G. (1995) *Proc. Natl. Acad. Sci. USA* 92, 6319–6323.
- [9] Pratt, W.B. (1993) *J. Biol. Chem.* 268, 21455–21458.
- [10] Franke, E.K., Yuan, H.E.H. and Luban, J. (1994) *Nature* 372, 359–362.
- [11] Thali, M., Bukovsky, A., Kondo, E., Rosenwirth, B., Walsh, C.T., Sodroski, J. and Gottlinger, H.G. (1994) *Nature* 372, 363–365.
- [12] Baker, E.K., Colley, N.J. and Zuker, C.S. (1994) *EMBO J.* 13, 4886–4895.
- [13] Haendler, B., Hofer-Warbinek, R. and Hofer, E. (1987) *EMBO J.* 6, 947–950.
- [14] Tropschug, M., Nicholson, D.W., Hartl, F.-U., Köhler, H., Pfanner, N., Wachter, E. and Neupert, W. (1988) *J. Biol. Chem.* 263, 14433–14440.
- [15] Schreiber, S.L. (1992) *Cell* 70, 365–368.
- [16] Tropschug, M., Barthelmess, I.B. and Neupert, W. (1989) *Nature* 342, 953–955.
- [17] Yokoyama, N., Hayashi, N., Seki, T., Panté, N., Ohba, T., Nishii, K., Kuma, K., Hayashida, T., Miyata, T., Fukui, M. and Nishimoto, T. (1995) *Nature* 376, 184–188.
- [18] Anderson, S.K., Gallinger, S., Roder, J., Frey, J. and Young, H.A. (1993) *Proc. Natl. Acad. Sci. USA* 90, 542–546.
- [19] Price, E.R., Zydowsky, L.D., Jin, M., Baker, C.H., McKeon, F.D. and Walsh, C.T. (1991) *Proc. Natl. Acad. Sci. USA* 88, 1903–1907.
- [20] Bergsma, D.J., Eder, C., Gross, M., Kersten, H., Sylwester, D., Appelbaum, E., Cusimano, D., Livi, G.P., McLaughlin, M.M., Kasyan, K., Porter, T.G., Silverman, C., Dunnington, D., Hand, A., Prichett, W.P., Bossard, M.J., Brand, M. and Levy, M.A. (1991) *J. Biol. Chem.* 266, 23204–23214.
- [21] Bischoff, F.R., Maier, G., Tilz, G. and Ponstingl, H. (1990) *Proc. Natl. Acad. Sci. USA* 87, 8617–8621.
- [22] Smith, D.B. and Johnson, K.S. (1988) *Gene* 67, 31–40.
- [23] Sugita, M. and Sugiura, M. (1994) *Nucleic Acids Res.* 22, 25–31.
- [24] Fischer, G., Bang, H. and Mech, C. (1984) *Biomed. Biochim. Acta* 43, 1101–1111.
- [25] Mattaj, I. (1993) *Cell* 73, 837–840.
- [26] Dreyfuss, G., Matunis, M.J., Pinol-Roma, S. and Burd, C.G. (1993) *Annu. Rev. Biochem.* 62, 289–321.
- [27] Krämer, A. (1996) *Annu. Rev. Biochem.* 65, 367–409.
- [28] Schönbrunner, E.R., Mayer, S., Tropschug, M., Fischer, G., Takahashi, N. and Schmid, F.X. (1991) *J. Biol. Chem.* 266, 3630–3635.
- [29] Champion-Arnaud, P. and Reed, R. (1994) *Genes Dev.* 8, 1974–1983.
- [30] Hirose, T., Sugita, M. and Sugiura, M. (1993) *Nucleic Acids Res.* 21, 3981–3987.
- [31] Sachs, A.B., Bond, M.W. and Kornberg, R.D. (1986) *Cell* 45, 827–835.
- [32] Kieffer, L.J., Seng, T.W., Li, W., Osterman, D.G., Handschumacher, R. and Baynea, R.M. (1993) *J. Biol. Chem.* 268, 12303–12310.
- [33] Lu, K.P., Hanes, S.D. and Hunter, T. (1996) *Nature* 380, 544–547.
- [34] Rahfeld, J.-U., Schierhorn, A., Mann, K. and Fischer, G. (1994) *FEBS Lett.* 343, 65–69.
- [35] Hani, J., Stumpf, G. and Domdey, H. (1995) *FEBS Lett.* 365, 198–202.